Pfizer is set to make around $15 billion from its COVID vaccine this year, but going forward the firm expects mRNA to be key in other applications. Through its partnership with BioNTech, Pfizer became the first company to receive US and EU approval for a messenger RNA-based product, namely the COVID-19 vaccine BNT162b2. Rollout of the vaccine continues across the globe and as such Pfizer has estimated it will realize approximately $15 billion in sales in 2021 alone. Speaking at…
CRISPR Therapeutics says the conditioning agent busulfan is unlikely to be the cause of adverse events that prompted Bluebird Bio to halt LentiGlobin trials. As a medicine busulfan is used to treat chronic myelogenous leukemia. It works by slowing or stopping the growth of cancerous cells. It is also used in cell and gene therapy as a conditioning agent to destroy bone marrow to prepare patients for transplant. Busulfan hit the headlines this month after Bluebird Bio started investigating it as…
Cell and Gene Therapy Catapult says GlaxoSmithKline is expanding its clinical trial manufacturing capacity in Stevenage, UK to drive its gene therapy pipeline.  No financial details have been disclosed, however through this agreement GSK is set to leverage the Cell and Gene Therapy Catapult (CGT Catapult) Stevenage facility to improve its GMP cell processing network and, in turn, streamline technical transfer and develop its gene therapy pipeline. “GSK is the seventh collaborator to join and this increases further the breadth…